Interactions of spironolactone with (+)‐[<sup>3</sup>H]‐isradipine and (−)‐[<sup>3</sup>H]‐desmethoxyverapamil binding sites in vascular smooth muscle

Mironneau, Jean; Sayet, I.; Rakotoarisoa, Lala; Dacquet, Catherine; Mironneau, C.

doi:10.1111/j.1476-5381.1990.tb12077.x

Cited by 7 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If this is the case, spironolactone may attenuate the cardiovascular actions of Ang II that are mediated via aldosterone receptors. Furthermore, blockade of mineralocorticoid receptors may affect intracellular sodium concentrations, and spironolactone itself has been reported to interact with the calcium-channel complex by partially inhibiting the specific binding of radiolabelled isradipine and verapamil (25,26), which suggests that spironolactone may affect cardiovascular cell growth or extracellular matrix formation, or both, and degradation by activating collagenase.…”

Section: Discussionmentioning

confidence: 99%

Differential Effects of Angiotensin II and Aldosterone on Cardiovascular Hypertrophy.

1994

View full text Add to dashboard Cite

The objective of this study was to determine the relative importance of angiotensin II (Ang II) and aldosterone in cardiovascular hypertrophy. Rats were given an infusion of Ang II (200 ng/kg/min) subcutaneously for 8 weeks with a mini-osmotic pump, with or without oral spironolactone (200 mg/kg) or MK-954 (30 mg/kg) daily. Ang II infusion resulted in marked hypertension of around 207 mmHg, which was associated with cardiac hypertrophy, with a heart-to-body-weight ratio of 0.35 ± 0.005% and thoracic aorta medial thickness of 0.166 ± 0.005 mm (vs. 0.285 ± 0.002% and 0.113 ± 0.003 mm, respectively, in control rats). Concomitant administration of spironolactone or MK-954 reduced the blood pressure in rats given Ang II to the same degree (164 and 171 mmHg, respectively). Aldosterone receptor blockade by spironolactone prevented Ang II-induced cardiac hypertrophy (heart-to-body-weight ratio = 0.307 ± 0.009% , but the Ang II-receptor antagonist MK-954 did not (heart-to-body-weight ratio = 0.331 ± 0.007%), although aortic vascular wall thickening in rats given Ang II was attenuated by both drugs. Renal hypertrophy induced by Ang II was not completely normalized by either drug. These results suggest that blockade of mineralocorticoid receptors is more effective than antagonism of Ang II receptors in preventing cardiac hypertrophy, and is as effective as antagonism of Ang II receptors in reducing vascular medial hypertrophy. They also indicate that, in addition to Ang II, aldosterone may play a pivotal role in regulating the growth of cardiac myocytes and vascular smooth muscle cells during Ang II-dependent hypertension. (Hypertens Res 1994; 17 233-237)

show abstract

Section: Discussionmentioning

confidence: 99%

Differential Effects of Angiotensin II and Aldosterone on Cardiovascular Hypertrophy.

1994

View full text Add to dashboard Cite

show abstract

Zinc ions efflux from lymphocytes in vitro in the presence of a calcium and magnesium ionic environment and its changes following administration of verapamil

Tubek¹

2007

Biol Trace Elem Res

View full text Add to dashboard Cite

The total and ouabain-dependent rate constants of efflux of zinc (Zn) ions from lymphocytes isolated from healthy subjects were measured in vitro in an environment containing calcium (Ca) and magnesium (Mg) ions. Both the total (ERCt-Zn) and ouabain-dependent (ERCos-Zn) rate constants were higher in the presence of Mg2+, with the the oubain-dependent efflux significantly different 0.29+/-0.07 vs 0.13+/-0.02 with and without Mg2+, respectively (p<0.001). After the addition of verapamil, an increase of ERCE-Zn was observed in both ionic environments and was higher and statistically significant in the presence of Mg2+: 1.94+/-0.64 vs 2.97+/-1.16 (p<0.025). These results suggest that verapamil has an enhancing effect on Zn efflux from isolated lymphocytes, suggesting that calcium channel blockers might result in better Zn homeostatic regulation in diseases of the cardiovascular system.

show abstract

Angiotensin-converting enzyme inhibitor and spironolactone combination therapy

Zannad

1993

The American Journal of Cardiology

View full text Add to dashboard Cite

Interactions of spironolactone with (+)‐[³H]‐isradipine and (−)‐[³H]‐desmethoxyverapamil binding sites in vascular smooth muscle

Cited by 7 publications

References 10 publications

Differential Effects of Angiotensin II and Aldosterone on Cardiovascular Hypertrophy.

Differential Effects of Angiotensin II and Aldosterone on Cardiovascular Hypertrophy.

Zinc ions efflux from lymphocytes in vitro in the presence of a calcium and magnesium ionic environment and its changes following administration of verapamil

Angiotensin-converting enzyme inhibitor and spironolactone combination therapy

Contact Info

Product

Resources

About

Interactions of spironolactone with (+)‐[3H]‐isradipine and (−)‐[3H]‐desmethoxyverapamil binding sites in vascular smooth muscle

Cited by 7 publications

References 10 publications

Differential Effects of Angiotensin II and Aldosterone on Cardiovascular Hypertrophy.

Differential Effects of Angiotensin II and Aldosterone on Cardiovascular Hypertrophy.

Zinc ions efflux from lymphocytes in vitro in the presence of a calcium and magnesium ionic environment and its changes following administration of verapamil

Angiotensin-converting enzyme inhibitor and spironolactone combination therapy

Contact Info

Product

Resources

About

Interactions of spironolactone with (+)‐[³H]‐isradipine and (−)‐[³H]‐desmethoxyverapamil binding sites in vascular smooth muscle